Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

Aromatase inhibitors (AIs) have greatly enriched the treatment of hormone receptor-positive breast cancer in postmenopausal patients. Before the introduction of the well-tolerated third-generation AIs, tamoxifen was the mainstay of endocrine therapy for hormone receptor-positive breast cancer. Many clinical trials have shown the superiority of AIs compared with tamoxifen in adjuvant breast cancer treatment, as well as their benefit in metastatic breast cancer. NCCN guidelines recommendations for their use are based on the evidence provided by these clinical trials. This discussion reviews the evidence supporting the current guidelines for use of AI therapy in the treatment of hormone receptor-positive postmenopausal breast cancer patients.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Richard L. Theriault, DO, MBA, Professor of Medicine, Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 424, Houston, TX 77030. E-mail: rtheriau@mdanderson.org

References

  • 1

    BeatsonGT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet1896;2:104107.

    • Search Google Scholar
    • Export Citation
  • 2

    FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:13711388.

    • Search Google Scholar
    • Export Citation
  • 3

    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet1998;351:14511467.

    • Search Google Scholar
    • Export Citation
  • 4

    SmithIE. Drug therapy: aromatase inhibitors in breast cancer. N Engl J Med2003;348:24312442.

  • 5

    KaufmannMBajettaEDirixLY. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol2000;18:13991411.

    • Search Google Scholar
    • Export Citation
  • 6

    BonneterreJBuzdarANabholtzJMA. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer2001;92:22472258.

    • Search Google Scholar
    • Export Citation
  • 7

    NabholtzJMABuzdarAPollakM. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol2000;18:37583767.

    • Search Google Scholar
    • Export Citation
  • 8

    MouridsenHGershanovichMSunY. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol2001;10:25962606.

    • Search Google Scholar
    • Export Citation
  • 9

    MouridsenHGershanovichMSunY. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol2003;21:21012109.

    • Search Google Scholar
    • Export Citation
  • 10

    ParidaensRDirixLLohrischC. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol2003;14:13911398.

    • Search Google Scholar
    • Export Citation
  • 11

    ParidaensRTherassePDirixL. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC Breast Group (Abstr #515). Proc Am Soc Clin Oncol2004;23.

    • Search Google Scholar
    • Export Citation
  • 12

    CarlsonRWEdgeSBMcCormickBTheriaultR. Clinical Practice Guidelines in Oncology version 1.2005. National Comprehensive Cancer Network.Available at http://www.nccn.org. Accessed April 18 2005.

    • Search Google Scholar
    • Export Citation
  • 13

    BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 14

    BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer2003;98:18021810.

    • Search Google Scholar
    • Export Citation
  • 15

    The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet2005;365:6062.

    • Search Google Scholar
    • Export Citation
  • 16

    WinerEPHudisCBursteinHJ. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol2005;23:619629.

    • Search Google Scholar
    • Export Citation
  • 17

    FisherBDignamJBryantJ. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst.2001;93:684690.

    • Search Google Scholar
    • Export Citation
  • 18

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 19

    CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 20

    EiermannWPaepkeSAppfelstaedtJ. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol2001;12:15271532.

    • Search Google Scholar
    • Export Citation
  • 21

    SemiglazovVFSemiglazovVVIvanovVG. Neoadjuvant endocrine therapy: exemestane (E) vs. tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4 N1-2 MO) (Abstr #111). Breast Cancer Res Treat2003;83(suppl 1):S22.

    • Search Google Scholar
    • Export Citation
  • 22

    SingletarySEAllredCAshleyP. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol2002;20:36283636.

    • Search Google Scholar
    • Export Citation
  • 23

    SemiglazovVFIvanovVGSemiglazovVV. Neoadjuvant endocrine therapy vs. chemotherapy for postmenopausal ER-positive breast cancer patients. Poster presentation at San Antonio Breast ConferenceSan Antonio, TX; December 9, 2004.

    • Search Google Scholar
    • Export Citation
  • 24

    RoseCVtorayaOPluzanskaA. An open randomized trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer2003;39:23182327.

    • Search Google Scholar
    • Export Citation
  • 25

    DunnBKWickerhamDLFordLG. Prevention of hormone-related cancers: breast cancer. J Clin Oncol2005;23:357367.

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 60 60 1
PDF Downloads 41 41 2
EPUB Downloads 0 0 0